Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS

Blood

Volumn 90, Issue 10, 1997, Pages 3853-3857

  De Witte, Theo ^a   Van Biezen, Anja ^b   Hermans, Jo ^b   Labopin, Myriam ^b   Runde, Volker ^b   Or, Reuven ^b   Meloni, Giovanna ^b   Mauri, Salut Brunet ^b   Carella, Angelo ^b   Apperley, Jane ^b   Gratwohl, Alois ^b   Laporte, Jean Pierre ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; AUTOTRANSPLANTATION; BONE TRANSPLANTATION; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; HEMATOPOIESIS; HUMAN; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RELAPSE; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ACUTE DISEASE; ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0030729822     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. De Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M, Jaksic B, Selleslag D, Zittoun R, Dardenne M, Solbu G, Zwierzina H, Muus P: Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myelogenous leukemia following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia 9:1805, 1995
2. Kantarjian HM, Keating MJ, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ: Therapy-related leukemia and myelodysplastic syndrome: Clinical, cytogenetic, and prognostic features. J Clin Oncol 4:1748, 1986
3. De Witte T, Muus P, De Pauw, Haanen C: Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer 66:831, 1990
4. De Witte T, Zwaan F, Hermans J, Vernant J, Kolb H, Vossen J, Lönnqvist B, Beelen D, Ferrant A, Gmür J, Liu Yin X, Troussard J, Cahn J, Van Lint M, Gratwohl A: Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: A survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 74:151, 1990
5. De Witte T, Gratwohl A: Bone marrow transplantation for myelodysplastic syndrome and secondary leukaemias. Annotation. Br J Haematol 84:361, 1993
6. Anderson JE, Appelbaum FR, Fisher LD, Schoch G, Shulman H, Anasetti C, Bensinger WI, Bryant E, Buckner CD, Doney K, Martin PJ, Sanders JE, Sullivan KM, Thomas ED, Witherspoon RP, Hansen JA, Storb R: Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 82:677, 1993
7. O'Donnell MR, Long GD, Parker PM, Nilaqnd J, Nademanee A, Amylan M, Chao N, Negrin RS, Schmidt GM, Slovak ML, Smith EP, Snyder DS, Stein AS, Traweek T, Blume KG, Forman SJ: Busulphan/cyclophosphamide as conditioning regimen for bone marrow transplantation for myelodysplasia. J Clin Oncol 13:2973, 1995
8. Geller RB, Vogelsang GB, Wingard JR, Yeager AM, Burns WH, Santos GW, Saral R: Successful marrow transplantation for acute myelocytic leukemia following therapy for Hodgkin's disease. J Clin Oncol 6:1558, 1988
9. Mc Millan AK, Goldstone AH, Linch DC, Gribben JG, Patterson KG, Richards JDM, Franklin I, Boughton BJ, Milligan DW, Leyland M, Hutchison RM, Newland AC: High dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia. Blood 76:480, 1990
10. Öberg G, Simonsson B, Smedmyr B, Björkstrand B, Colombat P, Coser P, Ferrant A, Goldstone AH, Helbig W, Löfvenberg E, McCarthy D, Polli E, Reifers J, Sundström C, Tötterman TH, Wahlin A, Wiesneth M: Is haematological reconstitution seen after ABMT in MDS patients? Bone Marrow Transplant 4:52, 1989 (suppl 2)
11. Laporte JP, Isnard F, Lesage S, Fenaux P, Douay L, Lopez M, Stacowiak J, Najman A, Gorin NC: Autologous bone marrow transplantation with marrow purged by mafosfamide in seven patients with myelodysplastic syndromes in transformation (AML-MDS): A pilot study. Leukemia 7:2030, 1993
12. Gorin NC, Aegerter P, Auvert B, Meloni G, Goldstone AH, Burnett A, Carella A, Korbling M, Herve P, Maraninchi D, Löwenberg R, Verdonck LF, De Planque M, Hermans J, Helbig W, Porcellini A, Rizzoli V, Alesandrino EP, Franklin IM, Reiffers J, Collesini P, Goldman JM: Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: A European survey of the role of marrow purging. Blood 75:1606, 1990
13. Bennett JM, Catovsky D, Daniel MD, Flandrin G, Galton DAG, Gralnick HR, Sultan C (FAB Cooperative Group): Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189, 1982
14. Michels SD, Samur J, Arthur DC, Robinson L, Brunning R: Refractory anemia with excess of blasts in transformation. Hematologic and clinical study of 52 patients. Cancer 64:2340, 1989
15. Preisler HD, Raza M, Barcos M, Azarnia N, Larson R, Browman G, Walker I, Grunwald H, D'Arrigo P, Stein A, Bloom M, Goldberg J, Gottlieb A, Bennett J, Kirshner J, Priore R: High-dose cytosine arabinoside in the treatment of preleukemic disorders: A leukemia intergroup study. Am J Hematol 23:131, 1986
16. Estey E, Pierce S, Kantarjian H, O'Brien S, Beran M, Andreeff S, Escudier S, Kollier C, Kornblau S, Roberetson L, Keating M: Treatment of myelodysplastic syndromes with AML-type chemotherapy. Leuk Lymphoma 11:59, 1993 (suppl 2)
17. Bernstein SH, Brunetto VL, Davey FR, Wurster-Hill D, Mayer RJ, Stone RM, Schiffer CA, Bloomfield CD: Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined French-American-British criteria: A Cancer Leukemia Group B study. J Clin Oncol 14:2486, 1996
18. Estey E, Thall P, Kantarjian H, Keating M, Pierce M, Geran UT: Diagnosis of RAEB or RAEB-t, rather than AML, does not negatively influence outcome of anti-AML chemotherapy. Blood 88:292a, 1996 (abstr 1155, suppl 1)
19. Armitage O, Dick FR, Needleman SW, Burns CP: Effect of chemotherapy for the dysmyelopoietic syndrome: Cancer Treat Rep 65:601, 1981
20. Fenaux P, Morel P, Rose C, Laï JL, Jouet JP, Bauters F: Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 77:497, 1991
21. Tricot G, De Bock R, Dekker AW, Boogaerts MA, Peetermans M, Punt K, Verwilghen RL: The role of aggressive chemotherapy in the treatment of myelodysplastic syndromes. Br J Haematol 63:477, 1986
22. Mertelsmann R, Thaler HT, To L, Gee TS, McKenzie S, Schauer P, Arlin Z, Cirrincione C, Clarkson B: Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood 56:773, 1980
23. Delforge M, Demuynck H, Vandenberghe P, Verhoef G, Zachee P, Duppen VV, Marijnen P, van den Berghe H, Boogaerts MA: Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood 86:3660, 1995
24. De Witte T, Suciu S, Boogaerts M, Labar B, Archimbaud E, Aul C, Selleslag D, Ferrant A, Weijermans P, Mandelli F, Amadori S, Jehn U, Muus P, Demuynck H, Dardenne M, Willemze R, Gratwohl A, Apperley J: The influence of cytogenetic abnormalities on treatment outcome after intensive antileukemic therapy for patients with high risk MDS and AML following MDS. A joint study of the EORTC, EBMT, SAKK, GIMEMA Leukemia Groups. Blood 88:454a, 1996 (abstr 1806, suppl 1)
25. Demuynck H, Delforge G, Verhoef P, Zachee P, Vandenberghe P, Van den Berghe H, Boogaerts M: Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes. Br J Haematol 92:351, 1996
26. Anderson JE, Anasetti E, Appelbaum FR, Schoch G, Gooley TA, Hansen JA, Buckner D, Sanders JE, Sullivan KM, Storb R: Unrelated donor transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukemia. Br J Haematol 93:59, 1996